| Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y |
MED's first-quarter results show challenges from fewer active OPTAVIA Coaches. Nonetheless, the company is focusing on revitalizing its coach base for growth. |
zacks.com |
2025-04-29 14:01:14 |
Czytaj oryginał (ang.) |
| Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript |
Medifast, Inc. (NYSE:MED ) Q1 2025 Earnings Conference Call April 28, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and CEO Jim Maloney - Chief Financial Officer Nick Johnson - Chief Field Operations Officer Conference Call Participants Jim Salera - Stephens Doug Lane - Water Tower Research Operator Greetings. And welcome to the Medifast First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-04-28 22:03:44 |
Czytaj oryginał (ang.) |
| Medifast Announces First Quarter 2025 Financial Results |
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (Nasdaq: LFMD) common stock of $0.4 million (n. |
businesswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| Medifast to Report Q1 Earnings: What Investors Should Expect |
MED's first-quarter results may show challenges in customer acquisition amid market headwinds and shifting consumer trends. |
zacks.com |
2025-04-21 14:10:36 |
Czytaj oryginał (ang.) |
| Medifast Trades Near 52-Week Low: What's the Best Move Now? |
MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives. |
zacks.com |
2025-04-15 16:10:39 |
Czytaj oryginał (ang.) |
| Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect |
Medifast, Inc.'s business is deteriorating as GLP-1 medication has lowered demand, causing a vicious flywheel effect as coaches are exiting the platform. The company is trying to reposition itself as a GLP-1 adjacent business, but the repositioning hasn't shown results so far with a deteriorating immediate earnings outlook. MED stock now trades below the company's net cash position, but due to high earnings uncertainty, the low valuation is justified. |
seekingalpha.com |
2025-03-28 11:21:43 |
Czytaj oryginał (ang.) |
| MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition |
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term. |
zacks.com |
2025-02-19 15:05:20 |
Czytaj oryginał (ang.) |
| Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript |
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-18 21:06:53 |
Czytaj oryginał (ang.) |
| Medifast (MED) Q4 Earnings and Revenues Beat Estimates |
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago. |
zacks.com |
2025-02-18 20:56:08 |
Czytaj oryginał (ang.) |
| Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chie. |
businesswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges |
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space. |
zacks.com |
2025-01-22 12:46:32 |
Czytaj oryginał (ang.) |
| Medifast Launches OPTAVIA ASCEND for Weight Loss Management |
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching. |
zacks.com |
2025-01-08 09:56:14 |
Czytaj oryginał (ang.) |
| Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off |
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE:MED), the health and wellness company known for its habit based and coach-guided lifestyle solution OPTAVIA, today announced OPTAVIA ASCEND — a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle hea. |
businesswire.com |
2025-01-07 10:30:00 |
Czytaj oryginał (ang.) |
| Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications |
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessar. |
businesswire.com |
2024-12-05 10:30:00 |
Czytaj oryginał (ang.) |
| How Should You Play Medifast Stock at a P/E Multiple of 17.6X? |
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success. |
zacks.com |
2024-11-19 13:00:32 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing MEDIFAST (MED) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-07 12:45:41 |
Czytaj oryginał (ang.) |
| Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued |
Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share. |
seekingalpha.com |
2024-11-06 10:02:26 |
Czytaj oryginał (ang.) |
| MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges |
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter. |
zacks.com |
2024-11-05 09:35:17 |
Czytaj oryginał (ang.) |
| Medifast (MED) Beats Q3 Earnings and Revenue Estimates |
Medifast (MED) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $2.12 per share a year ago. |
zacks.com |
2024-11-04 20:46:30 |
Czytaj oryginał (ang.) |
| Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript |
Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-04 19:56:31 |
Czytaj oryginał (ang.) |
| Medifast Gears Up for Q3 Earnings: Here's What You Should Know |
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications. |
zacks.com |
2024-11-01 12:56:14 |
Czytaj oryginał (ang.) |
| Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2024 |
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Offi. |
businesswire.com |
2024-10-21 20:05:00 |
Czytaj oryginał (ang.) |
| Medifast Drives Growth With Weight Loss Transformation Strategies |
MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges. |
zacks.com |
2024-10-07 17:11:11 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc. |
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-03 15:00:00 |
Czytaj oryginał (ang.) |
| Medifast Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Reach Out To The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-02 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Urges Shareholders To Join An Inquiry Into Medifast, Inc. For Possible Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-01 15:00:00 |
Czytaj oryginał (ang.) |
| Medifast Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Invited To Help The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-30 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc. |
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-29 15:00:00 |
Czytaj oryginał (ang.) |
| Medifast Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-28 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc. |
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-27 15:00:00 |
Czytaj oryginał (ang.) |
| Medifast Inc Is Being Investigated For Violating Securities Laws And Investors Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-26 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Medifast, Inc. For Possible Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-25 15:00:00 |
Czytaj oryginał (ang.) |
| Medifast Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-24 15:00:00 |
Czytaj oryginał (ang.) |